Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may cut hospital stays for preeclampsia

NCT ID NCT03289611

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a blood test measuring the sFlt-1/PlGF ratio can help doctors decide the best care for pregnant people with suspected preeclampsia before 35 weeks. 84 participants were randomly assigned to have their care guided by the test or usual care. The goal was to see if the test could reduce hospital stays and costs while keeping mothers and babies safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sFlt-1/PlGF ratio blood test
What this could lead to
If successful, this test could help doctors decide who needs hospital care for preeclampsia, reducing unnecessary stays and costs.
What could go wrong
This is a small, completed study with 84 participants. The test may not be accurate enough for all patients, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

84 people

The number who actually took part.

Started

Apr 2018

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient hospitalized for suspected preeclampsia between 24WG+ 0 days and 35WG + 6 days, Patiente with at least one of the following criteria: * Arterial hypertension defined by systolic BP ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg * Proteinuria greater than 0.3g / 24h or 0.3g / l or ≥ 3+ * Proteinuria / creatinine ratio ≥ 30 mg / mmol * Pain in the epigastric bar * Generalized edema * Hepatic cytolysis\> 1.5N * Thrombocytopenia \<150000 / mm3 Informed consent signed by both parties Non-opposition was accepted by parental authority Age ≥ 18 years Exclusion Criteria: Diagnosis of preeclampsia (arterial pressure\> 140/90 and proteinuria\> 0.3g / 24h or urine test\> 3+) or complete HELLP syndrome (Platelets \<100000 / mm3 and SGOT\> 2N and LDH and collapsed Haptoglobin) IUGR with absent or reverse diastolic umbilical flow Fetal heart rate abnormalities Gestational age \<24 WG and\> 35 WG Multiple pregnancy Patient without health insurance Non-consent of patient Minor patient Congenital malformation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia

Contacts and locations

Locations

  • CHU Cochin, Maternité Port Royal

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.